Insulin resistance may be diagnosed with markers such as high levels of C-peptide and/or fasting insulin, despite normal blood sugar levels. This can occur due to several physiological and pathological conditions, with the main culprit being the rising levels of insulin effectively clearing out excess glucose, which is what it is designed to do.

Low-dose naltrexone (LDN) is gaining attention as a potential therapeutic agent for chronic pain and inflammatory conditions. Originally approved by the FDA for opioid and alcohol dependence, naltrexone's mechanism of action at lower doses offers unique benefits in the management of inflammatory diseases such as multiple sclerosis (MS), fibromyalgia, and Crohn's disease. This article explores the scientific evidence surrounding LDN in these conditions.

Hashimoto's thyroiditis, an autoimmune disorder characterized by chronic inflammation of the thyroid gland, is the most common cause of hypothyroidism. This condition involves the immune system attacking the thyroid, leading to impaired thyroid function and various metabolic disturbances, including insulin resistance and increased cardiovascular risk. Recent research has suggested that metformin may offer benefits beyond glucose control, including anti-inflammatory and other therapeutic effects for patients with Hashimoto's thyroiditis. This article explores the scientific evidence supporting metformin's role in managing Hashimoto's thyroiditis.

Metformin, a well-known antidiabetic medication, has garnered interest for its benefits beyond glucose control. Its role in treating insulin resistance is particularly crucial for patients suffering from chronic inflammation, mold sickness, Chronic Inflammatory Response Syndrome (CIRS), and Mast Cell Activation Syndrome (MCAS), which are often triggered by toxin exposure and exacerbated by micro nutrient deficiencies such as low vitamin D. This article explores the scientific evidence supporting the use of metformin in these conditions.

An abundance of recent research indicates that metformin may have neuroprotective effects, making it a promising candidate for treating and preventing neurodegenerative diseases, neuroinflammation, dementia, and Alzheimer's. This article reviews recent scientific evidence from human studies, including those involving non-diabetic patients.

Current scientific evidence supports the potential of metformin and low dose naltrexone as therapeutic options for long COVID. Metformin's anti-inflammatory and metabolic regulatory effects, alongside LDN's neuroprotective and immune-modulatory properties, offer a promising strategy to mitigate long COVID symptoms.

Metformin has garnered significant attention for its potential anti-aging properties. Research indicates that metformin may influence various biological pathways associated with aging, suggesting its potential to extend healthspan and lifespan. This article explores the scientific evidence supporting metformin's role in anti-aging and longevity, focusing on recent human studies, including those in non-diabetic patients.

Metformin, a cornerstone in the treatment of insulin resistance, PCOS and type 2 diabetes, has shown promising potential in managing inflammatory and autoimmune disorders. This article delves into the scientific evidence supporting metformin’s benefits for these conditions, highlighting its anti-inflammatory and immunomodulatory properties, with a focus on studies conducted in humans.

Research has revealed a multitude of potential benefits of metformin that extend beyond its traditional use. These emerging applications have prompted interest in metformin as a therapeutic option for a variety of health conditions. This article explores how metformin has shown to improve a number of common conditions with supporting scientific evidence in non diabetic and diabetic patients.

Metformin has garnered interest for its potential cardiovascular benefits. While its efficacy in diabetic patients is well-documented, recent studies have explored its role in preventing and treating cardiovascular disease (CVD) in non-diabetic individuals. This article compiles scientific evidence from human studies to explore how metformin can help manage cardiovascular disease in non-diabetic patients.